Rigel Pharmaceuticals, Inc.

États‑Unis d’Amérique


 
Quantité totale PI 545
Rang # Quantité totale PI 2 416
Note d'activité PI 3/5.0    171
Rang # Activité PI 4 010
Symbole boursier
ISIN US7665596034
Capitalisation 408M  (USD)
Industrie Biotechnology
Secteur Healthcare
Classe Nice dominante Produits pharmaceutiques, vétéri...

Brevets

Marques

335 13
39 11
137 6
4
 
Dernier brevet 2025 - Heterocyclic rip1 inhibitory com...
Premier brevet 1994 - Method for selective inactivatio...
Dernière marque 2023 - REZLIDHIA
Première marque 1997 - RIGEL

Industrie (Classification de Nice)

Derniers inventions, produits et services

2024 Invention Heterocyclic rip1 inhibitory compounds. Disclosed herein are kinase inhibitory compounds, such a...
Invention Rip1 inhibitory compounds and methods for making and using the same. Disclosed herein are kinase...
Invention Treatment of acute myeloid leukemia with olutasidenib, venetoclax and a hypomethylating agent. Pr...
Invention Dosage regimens for the treatment of autoimmune and inflammatory diseases using ly3871801. Disclo...
Invention Ret inhibitor for use in treating cancer having a ret alteration. Disclosed herein are methods f...
Invention Use of a syk inhibitor for the treatment of chemical or radiation induced lung injury. Provided h...
Invention Use of a syk inhibitor for the treatment of sickle cell disease. Provided herein, among other thi...
Invention Inhibitors of ret. Described herein are compounds that inhibit wild-type RET and its resistant m...
2023 Invention Pyrazole compounds, formulations thereof, and a method for using the compounds and/or formulation...
Invention Bicyclic inhibitors of irak. Disclosed embodiments concern novel interleukin receptor associated...
Invention Bicyclic inhibitors of irak. Disclosed embodiments concern novel interleukin receptor associated ...
Invention Rip1k inhibitors. Disclosed herein are kinase inhibitory compounds, such as a receptor-interacti...
Invention Tricyclic irak inhibitors. Disclosed embodiments concern compounds according to Formula I In some...
Invention Tricyclic irak inhibitors. Disclosed embodiments concern compounds according to Formula I Disc...
Invention Pyrimid-2-yl-pyrazole compounds as irak inhibitors
Invention Pyrimid-2-yl-pyrazole compounds as irak inhibitors. Disclosed embodiments concern novel interleu...
Invention Pyrimid-2-yl-pyrazole compounds as irak inhibitors. Disclosed embodiments concern novel interleuk...
P/S Anti-cancer preparations; pharmaceutical products for the prevention and treatment of cancer; bio...
P/S Anti-cancer preparations; pharmaceutical products for the prevention and treatment of cancer; bi...
Invention Rip1k inhibitors. Disclosed herein are kinase inhibitory compounds, such as a receptor-interactin...
2022 Invention Crystalline forms of a ripk1 inhibitor. The present invention provides a crystalline compound of...
Invention Crystalline forms of a ripk1 inhibitor. The present invention provides a crystalline compound of ...
Invention 2,4-diamino-pyrimidine compounds and method for making and using the compounds. Compounds within...
Invention Amide compounds and method for making and using. Disclosed embodiments concern novel interleukin ...
Invention Tgf-β inhibitors. Disclosed are pyrazole compounds, as well as pharmaceutical compositions and me...
Invention Irak inhibitors and method for making and using. Disclosed embodiments concern interleukin recept...
Invention Heterocyclic rip1 kinase inhibitors. Disclosed herein are kinase inhibitory compounds, such as a...
Invention Rip1 inhibitory compounds and methods for making and using the same. Disclosed herein are kinase ...
Invention Irak inhibitor for treating cytokine release-related conditions associated with infection by a re...
Invention Method for treatment of an excessive immunological response to an infection by a respiratory viru...
Invention Pyrazole compounds and methods for making and using the compounds. Disclosed embodiments concern...
Invention Heterocyclic rip1 kinase inhibitors. Disclosed herein are kinase inhibitory compounds, such as a ...
Invention Method for treating a disease or condition using a pyrazole compound or formulation thereof. Dis...
Invention A method for treating a disease or condition using a pyrazole compound or formulation thereof. Di...
Invention Compounds and method for treating cytokine release syndrome. Disclosed herein are embodiments of...
2021 Invention Method of preparing pralsetinib. Provided herein, in part, are compounds and compositions useful...
P/S Medical information services; Providing information services in the field of the treatment of med...
Invention Tyrosine kinase inhibitors. Disclosed are imidazole compounds, as well as pharmaceutical composit...
Invention Solid forms of pralsetinib. The compound cis)-N—((S)-1-(6-(4-fluoro-1H-pyrazol-1-yl)pyridin-3-yl...
Invention Pralsetinib pharmaceutical compositions. The present disclosure relates to pharmaceutical compos...
P/S Administration of financial assistance and reimbursement programs, namely, administration of fina...
2020 P/S Pharmaceutical and medical preparations; pharmaceutical preparations for the treatment of immune ...
P/S Pharmaceutical preparations for the treatment of immune system diseases and disorders; pharmaceut...
2019 P/S Pharmaceutical preparations for the treatment of cancer
P/S Pharmaceutical preparations for the treatment of immune system diseases and disorders; Pharmaceut...
2018 P/S Pharmaceutical preparations for the treatment of cancer, auto-immune diseases, inflammatory disea...
P/S Pharmaceutical preparations for the treatment of cancer, immune disorders, inflammation, rare di...
P/S pharmaceutical preparations for the treatment of cancer, immune disorders, inflammation, rare dis...
P/S Providing a database for collecting and reporting information pertaining to medical treatment, in...
P/S Pharmaceutical preparations for the treatment of cancer, immune disorders, inflammation, rare dis...
2017 P/S Pharmaceutical preparations for the treatment of immune system diseases and disorders, namely, au...
P/S Pharmaceutical preparations for the treatment of immune system diseases and disorders; pharmaceu...
P/S Pharmaceutical preparations for the treatment of immunologic diseases, namely autoimmune diseases...
2001 P/S Pharmaceuticals for use in the treatment of [ viral diseases, ] cardiovascular and inflammatory d...
1998 P/S Pharmaceuticals for use in the treatment of viral diseases, cardiovascular and inflammatory disea...
1997 P/S Pharmaceutical for use in the treatment of viral diseases, cardiovascular and inflammatory diseas...
P/S research and development of technologies and scientific data in the field of new drug development...